Liraglutide Pancreatic Cancer

If you are or were using liraglutide and pancreatic cancer developed, talk to an experienced lawyer about your potential claim against the drugmaker. The type 2 diabetes drug more widely known by its brand name, Victoza, potentially puts those using it at a higher risk for developing the deadly disease as well as other life-threatening side effects and should be removed from the market.

What is Liraglutide?

Liraglutide, a once-daily injection, is a glucagon-like peptide-1 (GLP-1) receptor agonist that forces the pancreas to produce more insulin after consumption of a meal. Used with diet and exercise, liraglutide helps control blood sugar levels in some adults with type 2 diabetes. Drugmaker Novo Nordisk is also testing a high dose of the drug for its potential to induce and maintain weight loss in overweight type 2 diabetics.

FDA Approves Liraglutide Against Advice of Experts

Against the advice of its pharmacologists and clinical safety reviewer, the US Food and Drug Administration (FDA) approved Liraglutide in 2010. According to the FDA’s announcement, animal studies showed the drug caused thyroid cancer in rats and mice.

Clinical trials showed pancreatitis occurred more often in patients taking the drug than those taking other diabetes medications. Risk factors for pancreatitis can also put one at an increased risk of pancreatic cancer.

The Liraglutide Pancreatic Cancer Risk

One year after approval, the FDA issued a safety advisory warning about the serious risks associated with using the drug. The safety information warned medical practitioners to observe patients carefully after initiation of the drug for signs and symptoms of pancreatitis.

In April 2012, consumer advocacy group Public Citizen petitioned the US Food and Drug Administration (FDA) to remove liraglutide from the market because “it puts patients at higher risk of thyroid cancer, pancreatitis, serious allergic reactions and kidney failure that outweigh any documented clinical benefits.”

In March 2013, the FDA announced an investigation into a possible increased risk of pancreatitis and pre-cancerous cellular changes in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. Liraglutide is within that class of drugs. Read more about incretin mimetics and the risk for pancreatic cancer.

Pancreatic Cancer Lawsuit

Leading mass tort law firm Watts Guerra LLP is handling the nation’s largest incretins pancreatic cancer injury and wrongful death docket. The firm is representing clients who either developed or lost a family member to pancreatic cancer after using incretin-based therapies, including liraglutide.

The firm’s pharmaceutical lawyers, some of the country’s most experienced with product liability and mass tort claims, are reviewing liraglutide pancreatic cancer claims nationwide. If you or a family member used liraglutide or another incretin mimetic and were diagnosed with pancreatic cancer, contact the firm now.

Disclaimer: The images on this page of the Victoza packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Norvo Nordisk.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.
Contact us using our online form, or call us toll-free at 1(800)796-9605.